| Literature DB >> 27711131 |
Michaela Jakubkova1, Vladimira Dzugasova2, Dominika Truban1, Lenka Abelovska1,2, Ingrid Bhatia-Kissova1, Martin Valachovic3, Vlasta Klobucnikova3, Lucia Zeiselova2, Peter Griac3, Jozef Nosek1, Lubomir Tomaska2.
Abstract
Ionophores such as valinomycin and nigericin are potent tools for studying the impact of ion perturbance on cellular functions. To obtain a broader picture about molecular components involved in mediating the effects of these drugs on yeast cells under respiratory growth conditions, we performed a screening of the haploid deletion mutant library covering the Saccharomyces cerevisiae nonessential genes. We identified nearly 130 genes whose absence leads either to resistance or to hypersensitivity to valinomycin and/or nigericin. The processes affected by their protein products range from mitochondrial functions through ribosome biogenesis and telomere maintenance to vacuolar biogenesis and stress response. Comparison of the results with independent screenings performed by our and other laboratories demonstrates that although mitochondria might represent the main target for both ionophores, cellular response to the drugs is very complex and involves an intricate network of proteins connecting mitochondria, vacuoles, and other membrane compartments.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27711131 PMCID: PMC5053447 DOI: 10.1371/journal.pone.0164175
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Summary of the number of strains in each ionophore-resistance-related category identified in this study.
| Category | # mutants |
|---|---|
| NigR | 6 |
| NigHS | 14 |
| ValR | 64 |
| ValHS | 20 |
| ValR NigR | 8 |
| ValHS NigHS | 15 |
| Σ |
Fig 1Examples of strains exhibiting different sensitivity to ionophores compared with the wild-type.
Three microliters of the suspensions with the indicated concentrations of cells were spotted on the corresponding sSG media containing ionophores.
Functional groups enriched in the screen for mutants with altered sensitivity to ionophores.
| Category and function ( | Genes | k | f |
|---|---|---|---|
| GO biological process: | |||
| vacuole fusion, non-autophagic (1.5E-05) | 6 | 29 | |
| lipid biosynthesis (5.4E-05) | 7 | 52 | |
| regulation of SNARE complex assembly (1.3E-04) | 3 | 6 | |
| sterol biosynthesis (2.0E-04) | 2 | 29 | |
| response to reactive oxygen species (3.7E-04) | 1 | 2 | |
| piecemeal microautophagy of nucleus ((3.7E-04) | 5 | 23 | |
| GO Cellular Component: | |||
| HOPS complex (1.3E-04) | 3 | 6 | |
| cytosolic small ribosomal subunit (1.7E-04) | 7 | 62 | |
| MIPS Functional Classification: | |||
| superoxide metabolism | 1 | 2 | |
| tetracyclic and pentacyclic triterpenes metabolism | 5 | 36 | |
| MIPS Protein Complexes: | |||
| cytoplasmic ribosomal small subunit (9.8E-05) | 7 | 57 | |
| Vacuolar assembly complex (3.7E-04) | 2 | 2 | |
| Vam3/Vam7 vacuolar t-SNARE complex (3.7E-04) | 2 | 2 | |
| Yeast Fitness Data: | |||
| Slow growers (2.7E-13) | 40 | 616 |
* The P value reflects the probability that the observed annotation of the particular GO term to a group of genes occurs by chance [37] (http://funspec.med.utoronto.ca/cgi-bin/funspec); k, number of genes from the input cluster (127) in given category; f, number of genes total in given category; VR, valinomycin resistant; NR, nigericin resistant; VHS, valinomycin hypersensitive; NHS, nigericin hypersensitive; V+NHS, valinomycin and nigericin hypersensitive.
Fig 2All viable erg mutants exhibit changes in sensitivity to ionophores in both BY4741 and SCY325 genetic backgrounds.
(A) Growth of the mutant strains was assessed as described in Fig 1 and in Materials and Methods. (B) Scheme of the pathway of conversion of squalene to ergosterol and phenotypes of the mutants in term of their sensitivity to valinomycin and nigericin, respectively. RD, respiratory deficient.
Summary of the numbers of strains categorized based on the localization of the corresponding proteins (see also Fig 3). PM, plasma membrane; ER, endoplasmic reticulum, values in brackets include dual localizations.
| Localization | ValR | NigR | ValHS | NigHS | ValHSNigHS | ValRNigR | Σ | % |
|---|---|---|---|---|---|---|---|---|
| nucleus | 9 (13) | 1 (2) | 2 (2) | 1 (1) | 2 (2) | 0 (0) | 15 (20) | 11.8 (15.7) |
| ribosome | 9 (9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 9 (9) | 7.1 (7.1) |
| cytoplasm | 6 (13) | 1 (1) | 2 (2) | 0 (0) | 1 (2) | 1 (2) | 11 (20) | 8.7 (15.7) |
| PM | 4 (7) | 0 (0) | 1 (2) | 2 (2) | 0 (0) | 0 (0) | 7 (11) | 5.5 (8.7) |
| ER | 5 (7) | 0 (0) | 1 (3) | 1 (1) | 3 (3) | 1 (0) | 11 (14) | 7.9 (11.0) |
| mitochondria | 0 (4) | 1 (3) | 5 (8) | 2 (2) | 3 (4) | 3 (0) | 14 (21) | 11.0 (16.5) |
| vacuole | 1 (4) | 0 (0) | 1 (1) | 4 (4) | 0 (0) | 2 (0) | 8 (9) | 6.3 (7.1) |
| nucleolus | 3 (4) | 0 (0) | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 4 (5) | 3.1 (3.9) |
| Golgi apparatus | 2 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (2) | 1.6 (1.6) |
| other | 4 (6) | 1 (2) | 2 (2) | 1 (1) | 0 (0) | 0 (0) | 8 (11) | 6.3 (8.7) |
| dual | 6 | 2 | 2 | 0 | 0 | 0 | 10 | 7.9 |
| unknown | 12 | 0 | 4 | 2 | 3 | 2 | 23 | 18.1 |
Fig 3Distribution of localization of the proteins encoded by the genes whose deletion results in altered sensitivity to valinomycin and/or nigericin (see Table 3 for details).
Proteins with dual localization are counted twice (once for every localization) to reflect here every occurrence of the proteins in the cell.
Fig 4Genes whose absence leads to an altered sensitivity to valinomycin/nigericin as well as at least one of the following compounds: monensin [47], CTBT [48], oleic acid [50], and cationic drugs [52].
See also S5 Table.
Fig 5Organelle morphology in yeast cells treated with ionophores.
The wild-type strain (BY4741) and the corresponding transformants were cultivated in sSG medium. After addition of nigericin (15 mg/l) or valinomycin (15 mg/l) the cells were observed by fluorescence microscopy. Mitochondria were visualized using DiOC6 or mt-pHluorin (expressed from a plasmid) and vacuoles were stained with FM4-64, neutral red or Vba1-yEGFP3 (expressed from the plasmid pDF01).